Biosimilars: Company Strategies to Capture Value from the Biologics Market

Patents for several biologic blockbusters will expire in the next few years. The arrival of biosimilars, the biologic equivalent of chemical generics, will have an impact on the current biopharmaceuticals market. Five core capabilities have been identified as paramount for those companies aiming to...

Descripción completa

Detalles Bibliográficos
Autores principales: Calo-Fernández, Bruno, Martínez-Hurtado, Juan Leonardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816668/
https://www.ncbi.nlm.nih.gov/pubmed/24281342
http://dx.doi.org/10.3390/ph5121393
_version_ 1782477969570136064
author Calo-Fernández, Bruno
Martínez-Hurtado, Juan Leonardo
author_facet Calo-Fernández, Bruno
Martínez-Hurtado, Juan Leonardo
author_sort Calo-Fernández, Bruno
collection PubMed
description Patents for several biologic blockbusters will expire in the next few years. The arrival of biosimilars, the biologic equivalent of chemical generics, will have an impact on the current biopharmaceuticals market. Five core capabilities have been identified as paramount for those companies aiming to enter the biosimilars market: research and development, manufacturing, supporting activities, marketing, and lobbying. Understanding the importance of each of these capabilities will be key to maximising the value generated from the biologics patent cliff.
format Online
Article
Text
id pubmed-3816668
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-38166682013-11-14 Biosimilars: Company Strategies to Capture Value from the Biologics Market Calo-Fernández, Bruno Martínez-Hurtado, Juan Leonardo Pharmaceuticals (Basel) Article Patents for several biologic blockbusters will expire in the next few years. The arrival of biosimilars, the biologic equivalent of chemical generics, will have an impact on the current biopharmaceuticals market. Five core capabilities have been identified as paramount for those companies aiming to enter the biosimilars market: research and development, manufacturing, supporting activities, marketing, and lobbying. Understanding the importance of each of these capabilities will be key to maximising the value generated from the biologics patent cliff. MDPI 2012-12-12 /pmc/articles/PMC3816668/ /pubmed/24281342 http://dx.doi.org/10.3390/ph5121393 Text en © 2012 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Calo-Fernández, Bruno
Martínez-Hurtado, Juan Leonardo
Biosimilars: Company Strategies to Capture Value from the Biologics Market
title Biosimilars: Company Strategies to Capture Value from the Biologics Market
title_full Biosimilars: Company Strategies to Capture Value from the Biologics Market
title_fullStr Biosimilars: Company Strategies to Capture Value from the Biologics Market
title_full_unstemmed Biosimilars: Company Strategies to Capture Value from the Biologics Market
title_short Biosimilars: Company Strategies to Capture Value from the Biologics Market
title_sort biosimilars: company strategies to capture value from the biologics market
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816668/
https://www.ncbi.nlm.nih.gov/pubmed/24281342
http://dx.doi.org/10.3390/ph5121393
work_keys_str_mv AT calofernandezbruno biosimilarscompanystrategiestocapturevaluefromthebiologicsmarket
AT martinezhurtadojuanleonardo biosimilarscompanystrategiestocapturevaluefromthebiologicsmarket

Ejemplares similares